Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Johnson & Johnson (JNJ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Johnson & JohnsonTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Johnson & Johnson vs Neurocrine Biosciences Inc — how do they compare? Johnson & Johnson trades at $260.25 (market cap $626.09B), while Neurocrine Biosciences Inc trades at $156.5 (market cap $16.46B). The key difference: Johnson & Johnson is far larger — about 38× Neurocrine Biosciences Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

JNJNBIX
Market Cap
$626.09B$16.46B
Volume
6,156,228
Sector
HealthHealth
52-Week High
$267.24$185.50
52-Week Low
$172.78$123.10
Enterprise Value
$654.37B$16.48B
Dividend Yield
2.06%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.

Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX